Everence Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-5,620
| Closed | -$203K | – | 840 |
|
|
2024
Q4 | $203K | Sell |
5,620
-1,950
| -26% | -$70.4K | 0.01% | 780 |
|
|
2024
Q3 | $236K | Hold |
7,570
| – | – | 0.01% | 679 |
|
|
2024
Q2 | $228 | Hold |
7,570
| – | – | 0.02% | 644 |
|
|
2024
Q1 | $258 | Hold |
7,570
| – | – | 0.02% | 618 |
|
|
2023
Q4 | $219K | Hold |
7,570
| – | – | 0.02% | 674 |
|
|
2023
Q3 | $209 | Hold |
7,570
| – | – | 0.02% | 661 |
|
|
2023
Q2 | $251K | Hold |
7,570
| – | – | 0.02% | 580 |
|
|
2023
Q1 | $274 | Hold |
7,570
| – | – | 0.02% | 573 |
|
|
2022
Q4 | $270 | Hold |
7,570
| – | – | 0.02% | 587 |
|
|
2022
Q3 | $256K | Buy |
+7,570
| New | +$256K | 0.02% | 570 |
|
|
2022
Q2 | – | Sell |
-8,430
| Closed | -$272K | – | 763 |
|
|
2022
Q1 | $272K | Buy |
+8,430
| New | +$272K | 0.02% | 587 |
|
|
2021
Q3 | – | Sell |
-10,380
| Closed | -$320K | – | 765 |
|
|
2021
Q2 | $320K | Hold |
10,380
| – | – | 0.03% | 550 |
|
|
2021
Q1 | $272K | Hold |
10,380
| – | – | 0.02% | 591 |
|
|
2020
Q4 | $261K | Hold |
10,380
| – | – | 0.03% | 563 |
|
|
2020
Q3 | $216K | Hold |
10,380
| – | – | 0.02% | 563 |
|
|
2020
Q2 | $250K | Hold |
10,380
| – | – | 0.03% | 512 |
|
|
2020
Q1 | $187K | Buy |
+10,380
| New | +$187K | 0.03% | 528 |
|
|
2019
Q3 | – | Sell |
-7,020
| Closed | -$232K | – | 662 |
|
|
2019
Q2 | $232K | Hold |
7,020
| – | – | 0.04% | 506 |
|
|
2019
Q1 | $246K | Buy |
+7,020
| New | +$246K | 0.04% | 474 |
|
|
2018
Q3 | – | Sell |
-3,420
| Closed | -$205K | – | 450 |
|
|
2018
Q2 | $205K | Buy |
+3,420
| New | +$205K | 0.04% | 402 |
|